Advertisement
Employment/Membership › Details
PolyPeptide–Varray S: management, 202501– Chief Commercial Officer + Management Committee Member before Corden Pharma + Lonza
Period | 2025-01-01 | |
Organisation | PolyPeptide Group AG (SIX: PPGN) | |
Group | PolyPeptide (Group) | |
Organisation 2 | Corden Pharma (CordenPharma) (Group) | |
Product | contract manufacturing (drugs) | |
Person | Varray, Stéphane (PolyPeptide 202501– Chief Commercial Officer before Corden Pharma + Lonza) | |
PolyPeptide Group AG. (8/8/24). "Press Release: PolyPeptide Appoints Chief Commercial Officer". Baar.
PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleotide-based active pharmaceutical ingredients, today announced the appointment of Stéphane Varray as Chief Commercial Officer (CCO) and member of the PolyPeptide Management Committee (PMC).
As the peptide market is expected to grow rapidly, driven by GLP-1 therapies, there is a need to evolve PolyPeptide’s commercial capabilities and contract sophistication. In that context, PolyPeptide appointed Stéphane Varray as Chief Commercial Officer and as a member of the PolyPeptide Management Committee, effective January 2025.
Mr. Varray is a Swiss/French citizen and holds a PhD in Organic Chemistry from the University of Montpellier, France. He joins PolyPeptide from Corden Pharma, where he was responsible for the peptides platform. Before that, he had a successful career with Lonza, where he spent nearly two decades with growing commercial and leadership responsibilities in biologics and chemistry, including peptides.
Juan José González, CEO of PolyPeptide: “We are excited to welcome Stéphane to PolyPeptide. He is considered one of the most sophisticated commercial leaders in the peptide industry with an exceptional track record of delivering results and building high-performing teams. As we pursue our growth strategy, he will be instrumental in further strengthening our commercial agenda.”
Contact
PolyPeptide Group AG
Michael Stäheli
Head of Investor Relations & Corporate Communications
[email protected]
T: +41 43 502 0580
About PolyPeptide
PolyPeptide Group AG and its consolidated subsidiaries (“PolyPeptide”) is a focused Contract Development & Manufacturing Organization (CDMO) for peptide- and oligonucleotide-based active pharmaceutical ingredients. By supporting its customers mainly in pharma and biotech, it contributes to the health of millions of patients across the world. PolyPeptide offers products and services from pre-clinical through to commercial stages, including generics. Its active custom projects pipeline reflects the opportunities from novel drug therapies in development to fight both
widespread and rare diseases. Dating back to 1952, PolyPeptide today runs a global network of six GMP-certified facilities in Europe, the U.S. and India. PolyPeptide’s shares (SIX: PPGN) are listed on SIX Swiss Exchange. For more information, please visit polypeptide.com.
@PolyPeptide – follow us on LinkedIn
Disclaimer
This media release has been prepared by PolyPeptide Group AG and contains certain forward-looking statements that reflect the current views of management. Such statements are subject to known and unknown risks, uncertainties and other factors that may cause actual developments to differ materially from those expressed or implied in this release. PolyPeptide Group AG is providing the information in this release as of this date and, except as required by applicable laws or regulations, does not undertake any obligation to update any statements contained in it as a result of new information, future events or otherwise.
Record changed: 2024-08-08 |
Advertisement
More documents for PolyPeptide (Group)
- [1] PolyPeptide Group AG. (8/8/24). "Press Release: PolyPeptide Appoints Chief Commercial Officer". Baar....
- [2] PolyPeptide Group AG. (10/2/23). "Press Release: PolyPeptide Secures Revolving Credit Facility". Baar....
- [3] PolyPeptide Group AG. (8/15/23). "Press Release: Transformational Progress Taking Shape, Profitability Impacted by Rapid Expansion – Appointment of Marc Augustin as New CFO". Baar....
- [4] Numaferm GmbH. (5/9/23). "Press Release: PolyPeptide and Numaferm Announce Partnership to Leverage Their Expertise for the More Sustainable Production of Peptide-based APIs". Baar & Düsseldorf....
- [5] PolyPeptide Group AG. (4/3/23). "Press Release: PolyPeptide Appoints Juan-José Gonzalez as CEO and Announces Change of CFO". Baar....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top